Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using Alpelisib

Novartis

Status: Completed

Conditions: Breast Cancer

Treatments: Other: Piqray Prescriber's/HCP guide for hyperglycemia

Study type: Observational

Funder types: Industry

Identifiers

NCT05073120

CBYL719C2005

Details and patient eligibility

About

This was a multinational, non-interventional, cross-sectional survey conducted among HCPs based in the EU/EEA who prescribe Piqray. The survey assessed the knowledge of HCPs prescribing Piqray in relation to the management of hyperglycemia in patients treated with Piqray.

Enrollment: 103 patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Had prescribed Piqray to at least 1 locally advanced or MBC patient within 6 months prior to completing the survey.
• Provided permission to share their anonymized responses in aggregate with EMA or NCAs, if requested.

Exclusion criteria

HCPs who are direct employees of Novartis, the EMA (or any other regulatory bodies), or ICON.

Trial design

103 participants in 1 patient group

Piqray Prescriber's/HCP receiving the guide for hyperglycemia

Description:

HCPs prescribing Piqray in the EU/EEA provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material).

Treatment:

Other: Piqray Prescriber's/HCP guide for hyperglycemia